Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,284,762
  • Shares Outstanding, K 92,344
  • Annual Sales, $ 434,250 K
  • Annual Income, $ -606,640 K
  • EBIT $ -536 M
  • EBITDA $ -523 M
  • 60-Month Beta 0.58
  • Price/Sales 9.60
  • Price/Cash Flow N/A
  • Price/Book 11.99

Options Overview Details

View History
  • Implied Volatility 53.22% ( +2.11%)
  • Historical Volatility 35.71%
  • IV Percentile 51%
  • IV Rank 24.26%
  • IV High 110.63% on 04/12/24
  • IV Low 34.83% on 12/22/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 311
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 11,306
  • Open Int (30-Day) 12,430

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.33
  • Number of Estimates 11
  • High Estimate -1.09
  • Low Estimate -1.79
  • Prior Year -1.52
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.04 +8.74%
on 11/18/24
56.38 -16.99%
on 10/23/24
-7.66 (-14.07%)
since 10/21/24
3-Month
43.04 +8.74%
on 11/18/24
60.37 -22.48%
on 09/16/24
-10.25 (-17.97%)
since 08/21/24
52-Week
37.02 +26.42%
on 06/18/24
60.37 -22.48%
on 09/16/24
+7.96 (+20.49%)
since 11/21/23

Most Recent Stories

More News

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 49.37
2nd Resistance Point 48.17
1st Resistance Point 47.29
Last Price 46.66
1st Support Level 45.21
2nd Support Level 44.01
3rd Support Level 43.13

See More

52-Week High 60.37
Fibonacci 61.8% 51.45
Fibonacci 50% 48.69
Last Price 46.66
Fibonacci 38.2% 45.94
52-Week Low 37.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar